[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 43 of about 43

Advertisement
4. Eissa LA, Esmaeel MI: Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma. Pak J Pharm Sci; 2008 Jan;21(1):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma.
  • This study aimed to estimate the pretreatment serum levels of SVE-Cadherin, glycosaminoglycams (GAGs) and malondialdehyde (MDA) in order to evaluate their prognostic significance and their role in monitoring tumor response and overall-survival in Non Hodgkin lymphoma (DLCL) patients.
  • For this purpose pretreatment serum levels of these biochemical markers were evaluated in 40 newly diagnosed patients with non-Hodgkin lymphoma (Diffuse large cell type) and studied in relation to expression in healthy control.
  • Regarding response to therapy, only MDA showed a significant relation with response of the patient to treatment.
  • High level of MDA may be used as a predictor for tumor response to systemic chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Cadherins / blood. Glycosaminoglycans / blood. Lymphoma, Large B-Cell, Diffuse / blood. Malondialdehyde / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166516.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Glycosaminoglycans; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


5. Bobey NA, Stewart DA, Woodman RC: Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation. Leuk Lymphoma; 2002 Dec;43(12):2421-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation.
  • Posttransplant lymphoproliferative disorder (PTLD), a well recognized complication of organ transplantation, comprises a wide spectrum of heterogeneous lymphoid proliferations ranging from self-limiting mononucleosis through aggressive monoclonal non-Hodgkin's lymphoma (NHL).
  • There has been marginal success in treating PTLD using a number of treatment modalities, including combination chemotherapy.
  • There have been few reports of the use of high dose chemotherapy with stem cell rescue as a treatment for PTLD.
  • We report a renal allograft recipient who developed PTLD of the diffuse large cleaved B cell, NHL type.
  • Reduction of immunosuppression was initially effective, however the patient relapsed, and was treated successfully with CHOP chemotherapy.
  • This case illustrates a potential role for high dose chemotherapy with stem cell transplantation for the treatment of PTLD.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Immunosuppression / adverse effects. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Transplantation, Autologous


6. Kang KM, Chung WC, Lee KM, Hur SE, Nah JM, Kim GH, Back JY, Kim SK, Yang JM, Choi HJ: [A case of primary hepatic lymphoma mimicking hepatitis]. Korean J Hepatol; 2005 Sep;11(3):284-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepatic lymphoma mimicking hepatitis].
  • We report here on a case of non-Hodgkin's lymphoma in which liver involvement was the predominant clinical manifestation.
  • The abdominal CT scan showed only diffuse hepatosplenomegaly and uneven contrast enhancement of the spleen without any definite mass of the liver and spleen.
  • US-guided aspiration biopsy of liver and the histologic examination confirmed a diagnosis of non-Hodgkin's lymphoma, the diffuse large B cell type.
  • Bone marrow biopsy showed the infiltration of malignant lymphoma cells.
  • The patient was treated with combination regimen of cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy.
  • Even in the absence of a mass lesion or lymphadenopathy, primary hepatic or hepatosplenic lymphoma should be considered in differential diagnosis of hepatitis or liver cirrhosis, especially for patients with diffuse hepatosplenomegaly and markedly elevated LDH.
  • [MeSH-major] Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis


7. Hsieh PP, Tseng HH, Chang ST, Fu TY, Lu CL, Chuang SS: Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan. Leuk Lymphoma; 2006 Jan;47(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan.
  • Primary non-Hodgkin's lymphoma of bone (PLB) is a rare disorder representing less than 1% of all non-Hodgkin's lymphomas and has rarely been reported in Taiwan.
  • Histologically, 7 (50%) were diffuse large B-cell lymphomas (DLBCLs) and 5 (36%) anaplastic large cell lymphomas.
  • Seven patients received chemotherapy and radiotherapy; 4 chemotherapy and 3 radiotherapy alone.
  • Of the 11 patients with follow-up information, 6 (55%) died of disease within 1 year including 5 with T-cell lymphomas, while all the 5 patients surviving over 1 year were of B-cell phenotype.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Lineage. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Phenotype. Predictive Value of Tests. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Godt C, Regnery A, Schwarze B, Junker K, Porschen R: A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD). Z Gastroenterol; 2009 Mar;47(3):283-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD).
  • Post-transplant lymphoproliferative disorder (PTLD) is characterised by frequent extranodal manifestation, in 20 - 25 % including the gastrointestinal tract.
  • Further investigations revealed a diffuse infiltration of the liver, spleen, both kidneys and lungs.
  • Histologically, a monomorphic post-transplant lymphoproliferative disorder was diagnosed, the subtype was a high grade diffuse-large cell Non-Hodgkin's lymphoma of B-cell origin.
  • The current therapeutic approach to the subtype of PTLD we saw in this patient is CHOP chemotherapy, comprising the anti-CD 20 antibody rituximab if CD 20-positivity is present.
  • This patient had a fatal course of the disease and died a few days after the first chemotherapy cycle due to severe multiple organ failure.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Colitis, Ulcerative / etiology. Colorectal Neoplasms / diagnosis. Diarrhea / etiology. Gastrointestinal Hemorrhage / etiology. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


9. Shimatani H, Furukawa K, Ebihara Y, Serizawa H, Tsuboi M, Ogata A, Konaka C, Kato H: An early stage diffuse B-cell lymphoma within a visible site of bronchofiberscope accompanied by peripheral lung cancer. Diagn Ther Endosc; 2000;6(4):179-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An early stage diffuse B-cell lymphoma within a visible site of bronchofiberscope accompanied by peripheral lung cancer.
  • We report a case of non-Hodgkin's lymphoma found at the orifice of right B2 accompanied by peripheral lung cancer in a 66-year-old asymptomatic man.
  • The biopsy specimen from that site showed non-Hodgkin's lymphoma (diffuse B-cell type).
  • After left lower lobectomy, systemic chemotherapy was performed.
  • It is rare for malignant lymphoma to be recognized bronchofiberscopically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493536.001).
  • [ISSN] 1070-3608
  • [Journal-full-title] Diagnostic and therapeutic endoscopy
  • [ISO-abbreviation] Diagn Ther Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2362766
  •  go-up   go-down


10. Kyle F, Hill M: NHL (diffuse large B cell lymphoma). BMJ Clin Evid; 2008;2008
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NHL (diffuse large B cell lymphoma).
  • INTRODUCTION: Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line treatments for aggressive, or for relapsed aggressive, non-Hodgkin's lymphoma (diffuse large B cell lymphoma)?
  • We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
  • CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: allogeneic stem cell support, chemotherapy (conventional dose salvage, high-dose plus autologous transplant stem cell support, conventional dose in people with chemosensitive disease), CHOP 14, CHOP 21, CHOP 21 with radiotherapy, CHOP 21 with rituximab, MACOP-B, m-BACOD, PACEBOM, and ProMACE-CytaBOM.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Neoplasm Recurrence, Local
  • [MeSH-minor] Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Rituximab. Salvage Therapy


11. Pels H, Deckert-Schlüter M, Glasmacher A, Kleinschmidt R, Oehring R, Fischer HP, Bode U, Schlegel U: Primary central nervous system lymphoma: a clinicopathological study of 28 cases. Hematol Oncol; 2000 Mar;18(1):21-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a clinicopathological study of 28 cases.
  • A group of 28 consecutive patients (mean age 59 years) with primary central nervous system lymphoma (PCNSL) was treated with different regimens, including steroids only, radiotherapy (RT), chemotherapy or combinations of all.
  • Lymphoma was classified as high grade malignant B-cell non-Hodgkin's lymphoma of the diffuse large cell type in each of these cases.
  • RT alone led to tumour remission in more than 70 per cent, survival could be prolonged with additional chemotherapy.
  • Thirteen patients were treated with chemotherapy alone; nine of them received a novel combined intraventricular and systemic polychemotherapy protocol based on high dose methotrexate (MTX) and high dose cytarabine (ara-C).
  • Neurotoxicity, i.e. white matter lesions associated with severe cognitive dysfunction affected both patients surviving RT more than a year and patients treated with combination RT/chemotherapy.
  • Confluent white matter hyperintense lesions were detectable on MRI in three out of 13 patients treated with chemotherapy alone, however, cognitive dysfunction has not been detected in these patients.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Cognition Disorders / etiology. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Follow-Up Studies. Humans. Injections, Intraventricular. Male. Methotrexate / administration & dosage. Middle Aged. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / therapy. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Ltd.
  • (PMID = 10797527.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Suzuki K, Sai S, Kato K, Murase T: [A case of malignant lymphoma of the epididymis]. Hinyokika Kiyo; 2000 Apr;46(4):291-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma of the epididymis].
  • Histologically, the tumor was diagnosed as a malignant lymphoma (non-Hodgkin's lymphoma, diffuse mixed cell type, B-cell type).
  • After establishment of the diagnosis of primary epididymal malignant lymphoma, 3 courses of chemotherapy (adriamycin, vincristine, cyclophosphamide, prednisolone) were performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Epididymis. Lymphoma, B-Cell / surgery. Lymphoma, Non-Hodgkin / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Orchiectomy. Prednisolone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 9
  •  go-up   go-down


13. Takauchi K, Kono H, Ito T, Zaima K, Okumoto S: [A case of primary hepatic lymphoma successfully treated by THP-COP therapy]. Nihon Ronen Igakkai Zasshi; 2003 Jan;40(1):65-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepatic lymphoma successfully treated by THP-COP therapy].
  • The presence of a tumor mass in the umbilical portion of the liver was recognized by abdominal ultrasonography and computed tomography scan.
  • Needle biopsy of the tumor showed non Hodgkin's lymphoma (diffuse large B cell type) by histology and histoimmunology.
  • Primary hepatic lymphoma is so infrequent that standard treatments are not established yet.
  • Most cases of primary hepatic lymphoma are treated by surgical resection in Japan; however our conservative approach to remission is considered as very helpful for discussing how to treat primary hepatic lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Female. Humans. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649851.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


16. Portlock CS, Hamlin P, Noy A, Chey W, Gaydos CA, Palomba L, Schwartz I, Corcoran S, Rosenzweig L, Walker D, Papanicolaou G, Markowitz A: Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. Ann Oncol; 2008 Feb;19(2):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.
  • BACKGROUND: Eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tumor can result in lymphoma remission.
  • We prospectively identified/treated infections in nonbulky, advanced stage indolent lymphoma (follicular; nonfollicular lymphoma) eligible for observation.
  • MATERIALS AND METHODS: Stool H. pylori, hepatitis C and Borrelia serologies, Borrelia and Chlamydia fixed tissue PCR, Chlamydia peripheral blood mononuclear cell PCR and hydrogen breath test for small bowel bacterial overgrowth (SBBO) were obtained.
  • Lymphoma responses to antimicrobial therapy: H. pylori [one complete response (CR), 24+ months; one transient near CR]; hepatitis C [two CRs, 18+ and 30+ months; one partial response (PR) but hepatitis C virus persistent]; SBBO (one PR, 30+ months).
  • Patients with associated infections, but without lymphoma CR, have required lymphoma treatment sooner than those without initial infections (treatment-free survival at 23.4 months median follow-up, 40.5% versus 74.7%, P = 0.01), indicating a different biology.
  • CONCLUSION: Infections are common in advanced stage indolent lymphoma (37.5% in our series).
  • Anecdotal lymphoma responses have been seen and three have been durable CRs (18 to 30+ months) with infection eradication alone.
  • The identification and treatment of associated infections may be a first step towards developing a lymphoma prevention strategy.


17. Epure C, Ionascu L, Hagima N, Nan S, Stefaniu I: [Malignant non-Hodgkin diffuse lymphoma with extranodal orbital involvement--a clinical case]. Oftalmologia; 2005;49(4):29-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin diffuse lymphoma with extranodal orbital involvement--a clinical case].
  • The subsequent evolution of the disease required extensive investigations which provide the definitive diagnosis of non-Hodgkin, diffuse B-cell lymphoma, with extranodal orbital involvement.
  • In this case, the treatment of choice it must be systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Diagnosis, Differential. Female. Humans. Middle Aged. Prednisone / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524121.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


18. Novella G, Porcaro AB, Righetti R, Cavalleri S, Beltrami P, Ficarra V, Brunelli M, Martignoni G, Malossini G, Tallarigo C: Primary lymphoma of the epididymis: case report and review of the literature. Urol Int; 2001;67(1):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the epididymis: case report and review of the literature.
  • OBJECTIVE: To report an extremely rare clinical pathological observation of a case of primary lymphoma of the epididymis, without testicular or systemic involvement, and to update the relevant literature.
  • Epididymitis was diagnosed and conservative therapy with antibiotics and anti-inflammatory drugs was given.
  • After 2 months of therapy the patient was admitted to our department because a tumor was suspected.
  • RESULTS: High-grade primary epididymal non-Hodgkin's lymphoma with diffuse large cells (group G according to the Working Formulation) was diagnosed.
  • Clinical pathological staging detected stage IE (extranodal) primary epididymal lymphoma.
  • The patient was referred to the Hematologic Unit for combined chemotherapy, according to the VACOP-B protocol.
  • CONCLUSIONS: When an epididymal mass does not benefit from medical treatment, scrotal exploration and fresh frozen sections of the lesion should be done.
  • The possible bilateral involvement by primary epididymal lymphoma has to be kept in mind.
  • Radical orchiectomy is the treatment of choice for primary lymphoma of the epididymis.
  • Adjuvant chemotherapy is indicated in high-grade malignant lymphoma.
  • [MeSH-major] Epididymis. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11464129.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 5
  •  go-up   go-down


19. Kragelund CB, Søndergaard L, Bjerrum OW: [Primary cardiac lymphoma]. Ugeskr Laeger; 2001 Feb 26;163(9):1289-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma].
  • Primary cardiac non-Hodgkin lymphoma is very rare.
  • Results recently published suggest that the prognosis is good, if the lymphoma is diagnosed early.
  • A myocardial biopsy showed malignant non-Hodgkin lymphoma of the diffuse, large cell B-type.
  • The patient was treated with chemotherapy and control MRI after four treatments showed complete regression of the tumour.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11258255.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Takeuchi Y, Sawada Y, Yabuki D, Masuda E, Satou D, Iwasawa T, Kuroda K, Tajima M, Matsushima M: [Testicular malignant lymphoma: a case report]. Hinyokika Kiyo; 2003 Nov;49(11):675-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular malignant lymphoma: a case report].
  • We report a case of malignant lymphoma arising from the testicle in a patient who had been on chemotherapy for a long period after orchiectomy.
  • According to the histopathological diagnosis, the tumor was classified as non-Hodgkin's lymphoma, diffuse large cell type, B cell type.
  • Four courses of cycrophosphamide, adriamycin, vincristin and prednisolone (CHOP) therapy were administered.
  • COP (CHOP minus adriamycin) therapy has been given every four months on an out-patient basis.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse. Testicular Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Orchiectomy. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14719457.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


21. Qin L, Shi JH, Liu HR, Feng RE, Liu T, Li J, Lü W, Qin MW: [Non-Hodgkin's lymphoma with diffuse ground-glass opacity on chest CT: a report of 6 cases]. Zhonghua Yi Xue Za Zhi; 2010 Dec 14;90(46):3283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphoma with diffuse ground-glass opacity on chest CT: a report of 6 cases].
  • OBJECTIVE: To investigate the clinical, pathological and imaging characteristics, misdiagnosis and treatment of pulmonary non-Hodgkin's lymphoma with diffuse ground-glass opacities (GGO).
  • METHODS: Six cases of pulmonary non-Hodgkin's lymphoma with diffuse GGO on chest CT diagnosed from January 2008 to March 2010 were retrospectively analyzed.
  • Chest CT showed diffuse GGO (n=2), diffuse GGO with consolidations (n=3), with wide lung septum (n=3), with multiple nodules (n=2), with enlargement of mediastinal lymph nodes (n=2).
  • Histological findings including intravascular lymphoma (n=2), diffuse large B cell lymphoma (n=2) and T cell lymphoma (n=2).
  • Chemotherapy was administered in 4 patients with B cell lymphoma and all of them improved or remained stable.
  • One patient with T cells lymphoma was lost to follow-up and another patient with T cell lymphoma died due to lung infection.
  • CONCLUSIONS: Non-Hodgkin's lymphoma with diffuse GGO on chest CT scan is rare.
  • [MeSH-major] Lung / radiography. Lung Neoplasms / radiography. Lymphoma, Non-Hodgkin / radiography
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223788.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Hill M, Kyle F: NHL (diffuse large B-cell lymphoma). BMJ Clin Evid; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NHL (diffuse large B-cell lymphoma).
  • INTRODUCTION: Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line treatments for aggressive, or for relapsed aggressive, non-Hodgkin's lymphoma (diffuse large B-cell lymphoma)?
  • We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
  • CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: allogeneic stem-cell support, chemotherapy (conventional dose salvage, high-dose plus autologous transplant stem-cell support, conventional dose in people with chemosensitive disease), CHOP 14, CHOP 21, CHOP 21 with radiotherapy, CHOP 21 with rituximab, ACVBP, MACOP-B, m-BACOD, PACEBOM, and ProMACE-CytaBOM.
  • [MeSH-minor] Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Rituximab


23. Aoki Y, Tosato G: Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders. Curr Drug Targets Cardiovasc Haematol Disord; 2003 Mar;3(1):81-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders.
  • Since the advent of highly active antiretroviral therapy (HAART) and its widespread use, the incidence of AIDS-defining illnesses has decreased dramatically, leading to a much longer survival of patients.
  • Despite some exciting new leads, non-Hodgkin's lymphoma (NHL) remains a fatal malignancy for the vast majority of patients with acquired immunodeficiency syndrome (AIDS).
  • AIDS-associated lymphomas share several features, including B-cell lineage derivation, diffuse aggressive histology, and frequent origin from or involvement of extranodal sites.
  • KSHV is also thought to dramatically affect the incidence, type, and course of multicentric Castleman's disease, another lymphoproliferative disorder over-represented in patients with AIDS.
  • Deregulated cytokines may represent potential targets of novel therapeutic strategies.
  • [MeSH-major] Cytokines / physiology. Drug Delivery Systems / methods. Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Animals. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / physiopathology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12769647.001).
  • [ISSN] 1568-0061
  • [Journal-full-title] Current drug targets. Cardiovascular & haematological disorders
  • [ISO-abbreviation] Curr Drug Targets Cardiovasc Haematol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 178
  •  go-up   go-down


24. Ptushkin VV, Chimishkian KL, Zhukov NV, Osmanov DSh, Andreeva LIu, Tupitsyn NN, Larionova VB, Mkheidze DM, Poddubnaia NV: [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells]. Ter Arkh; 2003;75(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
  • AIM: To study efficacy of rituximab in patients with resistant B-cell lymphoma on high-dose chemotherapy.
  • MATERIAL AND METHODS: From September 2000 to April 2002 we studied efficacy and tolerance of rituximab at different stages of high-dose chemotherapy.
  • The treatment was given to 10 patients with histologically verified CD20+ non-Hodgkin's lymphoma: diffuse large-cell (n = 4), Berkitt's (n = 2), follicular (n = 3), mantle-cell (n = 1).
  • Five patients with diffuse large-cell lymphoma and Berkitt's lymphoma had a primary resistant course of the disease, one patient with diffuse large-cell lymphoma had a refractory recurrence.
  • The patients received 1-2 courses of induction chemotherapy with dexa-BEAM with collection of peripheral stem cells followed by high-dose chemotherapy (BEAM-9, CBV + mitoxantron-1) with transplantation of autologous stem blood cells.
  • Rituximab infusion (375 mg/m2) was conducted before the collection of the stem cells, prior to high-dose chemotherapy and in posttransplantation period after recovery of hemopoiesis.
  • 5 patients are in complete remission: 2 of them without further treatment, 3-after progression and repeat therapy including rituximab and interferon-alpha or rotuximab and CHOP chemotherapy.
  • CONCLUSION: The addition of rituximab can improve the results of high-dose chemotherapy of patients with non-Hodgkin's lymphoma resistant to standard doses of cytostatics.
  • Repeat use of this drug can be effective in some patients with progression after high-dose chemotherapy with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Rituximab

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12652962.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


25. Makishima H, Ito T, Kodama R, Asano N, Nakazawa H, Hirabayashi K, Nakamura S, Ota M, Akamatsu T, Kiyosawa K, Ishida F: Intestinal diffuse large B-cell lymphoma associated with celiac disease: a Japanese case. Int J Hematol; 2006 Jan;83(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal diffuse large B-cell lymphoma associated with celiac disease: a Japanese case.
  • Intestinal non-Hodgkin's lymphoma (NHL), especially the T-cell type, is well known to be associated with celiac disease (CD), an enteropathic disorder with a propensity for certain racial and genetic backgrounds.
  • We describe a Japanese middle-aged man with intestinal diffuse large B-cell lymphoma associated with CD.
  • Following multi-combined chemotherapy, the patient's lymphoma has been in a state of complete response, and his GI symptoms have improved with a GFD.
  • [MeSH-major] Celiac Disease / pathology. Intestinal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology


26. Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM, Wilson WH: Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review. Leuk Lymphoma; 2004 Dec;45(12):2521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review.
  • Job's or hyper immunoglobulin E recurrent infection syndrome (Hyper-IgE syndrome) is a rare, often inherited multisystem disorder, characterized by cutaneous abscesses, pneumonia, elevated IgE levels and skeletal defects.
  • He was found to have diffuse large B-cell lymphoma involving his second lumbar vertebrae and spleen.
  • Treatment with dose-adjusted EPOCH-rituximab (DA-EPOCH-R) chemotherapy achieved a complete remission after 4 cycles.
  • A review of reported cases of lymphoma in Job's syndrome indicates an increase in relative risk of 259 (95% confidence interval 102, 416).
  • The cause of the increased risk has yet to be defined but has similarities to a pathogenetic model of AIDS related lymphoma.
  • In previous reports of lymphoma in Job's syndrome, patients presented with extranodal disease and had poor outcomes.
  • With appropriate chemotherapy and hematological support, lymphoma associated with Job's syndrome can achieve complete remission.
  • [MeSH-major] Job Syndrome / complications. Lymphoma, Non-Hodgkin / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


27. Hernàndez DE, Hernàndez AE: Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor. Eur J Cancer Care (Engl); 2006 Dec;15(5):493-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
  • The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin's lymphoma (NHL) patients is very expensive in developing countries.
  • We treated 22 HIV-associated diffuse NHL patients with standard-dose CHOP and used G-CSF after an episode of febrile neutropenia until neutrophil count reached 1000/mm3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Fever / chemically induced. Fever / prevention & control. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Neutropenia / prevention & control. Prednisone / administration & dosage. Prednisone / adverse effects. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177909.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


28. Pascual JM, González-Llanos F, Roda JM: Primary hypothalamic-third ventricle lymphoma. Case report and review of the literature. Neurocirugia (Astur); 2002 Aug;13(4):305-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hypothalamic-third ventricle lymphoma. Case report and review of the literature.
  • She had a diffuse and homogeneous tumoral lesion involving the third ventricle and the adjacent hypothalamic area with marked enhancement after contrast administration on both, competed tomography scan and magnetic resonance images.
  • Histological diagnosis proved to be a diffuse non-Hodgkin lymphoma and the patient subsequently was treated with adjuvant radiotherapy and chemotherapy.
  • Treatment of PCNSL remains a challenge, and the topographical location within the hypothalamic-third ventricle area is even more complex.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Hypothalamus / pathology. Lymphoma, Non-Hodgkin / pathology. Third Ventricle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12355653.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 36
  •  go-up   go-down


29. Kornacker M, Kraemer A, Leo E, Ho AD: Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases. Ann Hematol; 2002 Feb;81(2):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.
  • Sarcoidosis-lymphoma syndrome is a well-established syndrome where sarcoidosis is followed by the development of a lymphoproliferative disease such as non-Hodgkin's lymphoma (NHL).
  • Here we report two patients with NHL who developed sarcoidosis subsequent to the diagnosis of lymphoproliferative disease.
  • In both cases, chemotherapeutic treatment had already been initiated or was completed when sarcoidosis occurred.
  • In these patients, sarcoidosis may have been triggered by immunologic aberrations induced by antineoplastic therapy or as a consequence of an underlying immunologic disturbance associated with the lymphoma.
  • When a suspected relapse of lymphoma presents with signs and symptoms compatible with sarcoidosis, this rare immunologic disorder has to be ruled out by careful clinical and histopathologic analysis to prevent mistreatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lung Diseases / chemically induced. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Sarcoidosis / chemically induced
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Clarithromycin / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Male. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11907791.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; H1250JIK0A / Clarithromycin; VB0R961HZT / Prednisone; CHOEP protocol; CHOP protocol
  •  go-up   go-down


30. Bölke E, Peiper M, Matuschek C, Schieren G, Glombick R, Förster C, Budach W, Orth K: Extranodal diffuse non hodgkin lymphoma in the thigh. Eur J Med Res; 2010 Aug 20;15(8):367-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal diffuse non hodgkin lymphoma in the thigh.
  • Diffuse large B-cell lymphoma usually starts as a rapidly growing mass in an internal lymph node and can grow in other areas such as the bone or intestines.
  • Biopsies of the tumour revealed diffuse proliferation of large lymphoid cells which have totally affected the normal architecture of striated muscle.
  • The patient received multimodality treatment including chemotherapy of the CHOP regimen and adjuvant radiotherapy.
  • Despite this being a fast growing lymphoma, about 3 out of 4 people will have no signs of disease after initial treatment, and about half of all people with this lymphoma are cured with therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Thigh


31. Hasegawa Y, Shirai S, Mishina T, Nakata M, Aikawa K, Yoshida K: [An elderly non-Hodgkin lymphoma patient with a massive tumor of the heart]. Rinsho Ketsueki; 2002 Jul;43(7):538-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly non-Hodgkin lymphoma patient with a massive tumor of the heart].
  • We report on an elderly patient with a malignant lymphoma forming a huge mass in the heart.
  • She was diagnosed as having non-Hodgkin lymphoma, diffuse large cell type, B-cell type.
  • Computed tomography scans showed a markedly thickened right ventricular wall of the heart, swollen lymph nodes of the mediastinum, bilateral pleural effusions, and a tumor in the spleen.
  • Lymphoma cells were found in the pleural effusion, and the lymphoma was diagnosed as clinical stage IV.
  • EF increased to 70% after 3 courses of chemotherapy with CHOP regimen.
  • All lesions disappeared after 6 courses of chemotherapy were completed.
  • After consolidative radiotherapy with a total dose of 37 Gy to the mediastinum and heart, bilateral pleural effusions, elevation of the patient's lactate dehydrogenase level and soluble IL-2 receptor value were recognized, which suggested relapse of the lymphoma, although histopathological confirmation could not be realized.
  • [MeSH-major] Heart Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy


32. Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T: Cytotoxic T-cell lymphoma arising in Behçet disease. Int J Hematol; 2003 Apr;77(3):282-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cell lymphoma arising in Behçet disease.
  • The case of a 49-year-old man with peripheral T-cell lymphoma arising in Behcet disease (BD) is reported.
  • A left perirenal mass emerged, and a computed tomography-guided needle biopsy of the tumor revealed the infiltration of small- and medium-sized lymphoma cells.
  • A diagnosis of non-Hodgkin's lymphoma (diffuse medium, T-cell) was made.
  • Standard combination chemotherapy diminished the perirenal and orbital lesions.
  • Lymphoma cell infiltration in the esophagus was detected after chemotherapy, and the patient died of massive bleeding from the gastrointestinal tract.
  • Non-Hodgkin's lymphoma is rarely associated with BD, and only 7 cases have been reported in the literature.
  • We have summarized the published case reports of malignant lymphoma arising in BD.
  • To our knowledge, this case report is the first to describe cytotoxic T-cell lymphoma arising in Behçet disease.
  • [MeSH-major] Behcet Syndrome / complications. Lymphoma, T-Cell / etiology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Antigens, CD / analysis. Clone Cells / immunology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):241-5 [9085175.001]
  • [Cites] Ann Rheum Dis. 2001 Nov;60(11):996-1002 [11602462.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] Arthritis Rheum. 1974 Jul-Aug;17(4):383-90 [4604718.001]
  • [Cites] No To Shinkei. 1992 Nov;44(11):1029-33 [1296716.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):296-301 [10680899.001]
  • [Cites] Int J Tissue React. 1988;10(2):59-65 [3053482.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):885-7 [2099715.001]
  • [Cites] N Engl J Med. 1999 Oct 21;341(17):1284-91 [10528040.001]
  • [Cites] Ann Intern Med. 1976 Jan;84(1):68-76 [1106291.001]
  • [Cites] Intern Med. 1993 Aug;32(8):663-7 [8312668.001]
  • [Cites] Clin Rheumatol. 2001;20(4):239-44 [11529628.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Rinsho Ketsueki. 1992 Feb;33(2):211-5 [1635171.001]
  • [Cites] Ann Rheum Dis. 1986 Sep;45(9):789 [3767471.001]
  • [Cites] Acta Pathol Jpn. 1974 Jan;24(1):141-50 [4406401.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1343-51 [6215926.001]
  • [Cites] Arthritis Rheum. 1982 Sep;25(9):1130-3 [7126297.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Oct;236(10):798-9 [9801898.001]
  • [Cites] Rinsho Ketsueki. 1997 Aug;38(8):657-62 [9311271.001]
  • [Cites] Nephron. 1999 Feb;81(2):239 [9933762.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1728-33 [8826934.001]
  • (PMID = 12731673.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunosuppressive Agents
  • [Number-of-references] 25
  •  go-up   go-down


33. Sehn LH, Connors JM: Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology (Williston Park); 2005 Apr;19(4 Suppl 1):26-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
  • The most common subtype of aggressive non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL).
  • Diffuse large B-cell lymphoma represents a heterogeneous entity, with 5-year overall survival rates ranging from 26% to 73%.
  • Approximately 25% of patients with DLBCL present with limited-stage disease and are treated with combined-modality therapy (brief chemotherapy and involved-field radiation).
  • Most patients present with advanced-stage disease and require treatment with an extended course of chemotherapy.
  • The CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone) chemotherapy regimen has been the mainstay of therapy since its development in the 1970s, as more intensive chemotherapy regimens failed to show additional benefit.
  • The era of monoclonal antibodies has transformed treatment practices for aggressive lymphoma and has led to a significant improvement in outcome.
  • A randomized trial comparing the use of rituximab (Rituxan), a chimeric anti-CD20 IgG1 monoclonal antibody, combined with CHOP chemotherapy vs CHOP chemotherapy alone for elderly patients with advanced-stage DLBCL demonstrated a significant benefitfor the combination approach.
  • Despite this advance, newer therapies are needed and many are under active investigation.
  • The insights gained from molecular techniques such as gene expression profiling should permit identification of additional lymphoma-specific therapeutic targets and the development of novel agents that take into account underlying biology and allow for greater tailoring of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934515.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 58
  •  go-up   go-down


34. Yoon JH, Lee YY, Park CG, Koe BH, Kim IS: A case of primary adrenal gland lymphoma. Korean J Intern Med; 2003 Jun;18(2):122-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary adrenal gland lymphoma.
  • Primary adrenal lymphoma is extremely rare.
  • We describe a case of non-Hodgkin's lymphoma of diffuse large B-cell type with right adrenal involvement.
  • The patient received chemotherapy and external irradiation and achieved complete remission of the disease.
  • We describe the case of primary adrenal lymphoma with a review of the literature on this unusual neoplasm.
  • Primary adrenal lymphoma should be included in the differential diagnosis of adrenal mass.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872452.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC4531612
  •  go-up   go-down


35. Yokoyama J, Fujimiya Y, Yamaguchi T, Shiga K, Saijo Y, Groveman DS, McBain JA, Suzuki Y, Ebina T: Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma. Am J Hematol; 2003 May;73(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma.
  • The most effective treatment for recurrent non-Hodgkin's lymphoma (NHL) appears to be a high-dose cytotoxic chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT).
  • However, it has been suggested that the presence of occult lymphoma cells in harvested marrow may be responsible for a significant fraction of treatment failures after HDC/ABMT.
  • Among 41 NHL patients examined, bcl-2/IgH translocations were evident in LN biopsies and marrow from each of 10 follicular lymphoma patients, but not in any samples from 31 newly diagnosed diffuse lymphoma patients.
  • Such outgrowth was specifically seen in cultures of diffuse lymphoma marrow (7 of 28 evaluable patients).
  • Southern analysis for IgH rearrangement within LN biopsies and of cells cultured from marrow of individual diffuse lymphoma patients produced identical patterns, suggesting that the occult lymphoma cells present in harvested marrow were derived from the predominant lymphoma cell population represented within involved lymph nodes.
  • The culture of histologically occult lymphoma from diagnostic marrow and analysis of the derived cells by Southern blot hybridization can be used to detect potentially aggressive lymphoma cells within harvested marrow, despite their lack of bcl-2 gene rearrangement.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoradiography. Biopsy. Blotting, Southern. Bone Marrow / pathology. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. DNA, Neoplasm / analysis. Deoxyribonuclease BamHI. Deoxyribonuclease EcoRI. Deoxyribonuclease HindIII. Female. Gene Rearrangement. Genes, bcl-2 / genetics. Genetic Markers. Humans. Immunoglobulin Heavy Chains / genetics. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Male. Middle Aged. Polymerase Chain Reaction. Translocation, Genetic. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12701113.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / Immunoglobulin Heavy Chains; EC 3.1.21.- / Deoxyribonuclease BamHI; EC 3.1.21.- / Deoxyribonuclease EcoRI; EC 3.1.21.- / Deoxyribonuclease HindIII
  •  go-up   go-down


36. Heintel D, Skrabs C, Hauswirth A, Eigenberger K, Einberger C, Raderer M, Sperr WR, Knöbl P, Müllauer L, Uffmann M, Dieckmann K, Gaiger A, Jäger U: Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol; 2010 Feb;89(2):163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used nonpegylated liposomal doxorubicin (NPLD) in cytostatic drug combinations to treat 37 patients with non-Hodgkin's lymphoma and pre-existing cardiac disorder or elderly patients with reduced physical state who were ineligible for conventional anthracycline-containing therapy.
  • High remission rates were observed in this poor-risk population: Complete remission rates were 75% for diffuse large B cell lymphoma (DLBCL) and 55% for T/NK cell neoplasm (overall response rate of 80% and 89%, respectively).
  • Twenty-seven patients (73%) are still alive after a median observation time of 14 months.
  • Extravasation of NPLD in two patients resulted in mild inflammation without tissue damage.
  • We conclude that NPLD is highly active in combination chemotherapy for lymphoma with low cardiac toxicity in patients with pre-existing cardiac disorders or higher age.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Heart Diseases / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636553.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


37. Fischbach W: [Gastric lyphoma - still a result of surgery?]. Chirurg; 2006 Jun;77(6):512, 514-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In extranodal non-Hodgkin's lymphoma (NHL), the gastrointestinal tract is by far the most frequent localization.
  • One must differentiate between primary lymphoma, e.g. those arising in the gastrointestinal tract, and secondary lymphoma, which can affect the digestive tract as a disseminations of nodal lymphoma.
  • Analysis of histomorphologic and immunhistochemical characteristics and the concept of mucosa-associated lymphoid tissue (MALT) have led to primary gastrointestinal lymphoma now being viewed as an independent entity.
  • The great majority of gastric lymphoma (>90%) are marginal zone B-cell lymphoma of the MALT type, previously called low grade MALT lymphoma, and diffuse large B-cell lymphoma, previously called high grade gastric lymphoma.
  • This review examines current views on pathogenesis, diagnosis, and therapy of this disorder.
  • [MeSH-major] Lymphoma. Stomach Neoplasms
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Biopsy. Combined Modality Therapy. Cyclophosphamide. Diagnosis, Differential. Doxorubicin. Helicobacter Infections / complications. Helicobacter pylori. Humans. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Neoplasm Staging. Prednisone. Prognosis. Prospective Studies. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Retrospective Studies. Rituximab. Stomach / pathology. Time Factors. Vincristine. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Internist (Berl). 2000 Sep;41(9):831-40 [11006870.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1174-80 [16329013.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Dtsch Med Wochenschr. 1997 Dec 12;122(50):1569-72 [9445780.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):28-37 [15213615.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):547-8 [12241663.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):696-700 [12397278.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • (PMID = 16773350.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 16
  •  go-up   go-down


38. Iida K, Tsutsumi M, Ishikawa S: [Metachronous primary malignant lymphoma of the bilateral tests: a case report]. Hinyokika Kiyo; 2002 Feb;48(2):93-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous primary malignant lymphoma of the bilateral tests: a case report].
  • We report a case of metachronous malignant lymphoma of the bilateral testes.
  • The histological examination confirmed non-Hodgkin's lymphoma of diffuse, large-sized cells of the B cell type.
  • Computed tomography of the abdomen revealed paracaval lymphandenopathy at stage IIE according to Ann Arbor classification.
  • Chemotherapy was initiated with cyclophosphamide, adriamycin and vincristine.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968735.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


39. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, Guy G, Lapierre F: Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg; 2000 Feb;92(2):261-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracerebral malignant lymphoma: report of 248 cases.
  • OBJECT: The authors present a retrospective analysis of 248 immunocompetent patients with primary intracerebral lymphoma treated at 19 French and Belgian medical centers between January 1980 and December 1995.
  • All tumors available for review were classic diffuse non-Hodgkin's lymphoma, for which the phenotype was determined in 220 patients: 212 (96.4%) were B-cell and eight (3.6%) were T-cell type tumors.
  • According to the Revised European-American classification of lymphoid neoplasms, most lesions were diffuse large cell tumors (62%).
  • A total of 196 tumors were reviewed in 127 patients for whom preoperative computerized tomography and magnetic resonance studies were available.
  • Of the 248 patients studied, 129 (52%) received chemotherapy plus radiation therapy, 60 (24%) received radiation therapy alone, 35 (14%) received chemotherapy alone, and 24 (10%) received no postsurgical treatment.
  • CONCLUSIONS: Using univariate analysis, the authors determined prognostic factors that were significantly associated with a favorable impact on survival including age younger than 60 years, radiation therapy (without evidence of a dose-response relationship), radiation therapy combined with chemotherapy, and chemotherapy consisting of anthracycline.
  • Multivariate analysis was used to confirm the independent prognostic value of radiation therapy, age, chemotherapy consisting of anthracyclines or methotrexate, and partial surgical resection.
  • This European survey provides a reasonable basis for the treatment of primary intracerebral lymphoma with the following sequence: stereotactic biopsy sampling, chemotherapy with a methotrexate- and anthracycline-based regimen, followed by cranial irradiation.
  • [MeSH-major] Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / pathology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


40. Ogino J, Kawakatsu C, Hirasawa A, Sato T, Kawamura S, Nishikawa T, Wakabayashi Y: [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade]. Rinsho Ketsueki; 2001 Nov;42(11):1101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade].
  • Abdominal ultrasonography and computed tomography revealed bilateral renal tumors.
  • Percutaneous needle biopsy of the left renal tumor was performed, and the final diagnosis was non-Hodgkin's lymphoma (diffuse mixed, B cell type, CSIIA).
  • After six courses of chemotherapy, the tumor lesions were markedly reduced, and at present there is no evidence of recurrence.
  • [MeSH-major] Hematuria / etiology. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808078.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Hokett SD, Cuenin MF, Peacock ME, Thompson SH, Van Dyke TE: Non-Hodgkin's lymphoma and periodontitis. A case report. J Periodontol; 2000 Mar;71(3):504-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma and periodontitis. A case report.
  • BACKGROUND: We describe an unusual case of extra-nodal non-Hodgkin's lymphoma that developed in the maxillae associated with localized severe periodontitis in a 64-year-old Caucasian male.
  • The lymphoma was diagnosed less than 2 years following routine periodontal surgery and 8 weeks after the extraction of hopeless teeth in the associated area.
  • A definitive biopsy diagnosis of high-grade, small, non-cleaved, diffuse non-Hodgkin's lymphoma of the right posterior maxillae was established.
  • The patient was subsequently treated by a combination of radiation, chemotherapy, and bone marrow transplantation.
  • RESULTS: The maxillary tissues healed uneventfully, and the patient has been closely observed for approximately 5 years without symptoms or recurrence of the lymphoma.
  • CONCLUSIONS: This case highlights the need for careful debridement of extraction sockets associated with severe periodontitis and argues for the routine submission of extracted teeth with adjacent soft tissue for microscopic analysis, to assist in the early diagnosis of potentially life-threatening malignancies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Maxillary Sinus Neoplasms / complications. Periodontitis / etiology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Periodontal Abscess / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10776941.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


42. Kim D, Ko Y, Suh Y, Koo H, Huh J, Lee W: Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea. Virchows Arch; 2005 Sep;447(3):593-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea.
  • To analyze the clinicopathologic characteristics of childhood non-Hodgkin's lymphoma (NHL) associated with Epstein-Barr virus (EBV), EBER in situ hybridization was performed in 80 cases of NHLs.
  • EBER-positive lymphomas account for 25% (20/80) and include NK/T-cell lymphoma (6/6), aggressive NK-cell leukemia (1/1), peripheral T cell lymphoma (5/11), diffuse large B-cell lymphoma (5/14), hydroa-like T-cell lymphoma (1/1), marginal zone B-cell lymphoma (1/2), and post-transplantation lymphoproliferative disorder (1/1).
  • Other types including 19 cases of Burkitt's lymphoma were negative.
  • Clinically, patients with EBV-positive B-cell lymphomas were cured with chemotherapy, whereas EBV-associated NK- and T cell lymphomas pursued fatal clinical course.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Lymphoma, Non-Hodgkin / virology. Tumor Virus Infections / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1233-40 [11123421.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):427-42 [11594706.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Pathol Int. 2004 Mar;54(3):151-7 [14989737.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1695-704 [6697306.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):283-8 [9042791.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):121-8 [9210717.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4244 [14623773.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Adv Cancer Res. 1993;62:179-239 [8109318.001]
  • [Cites] Blood Rev. 1993 Dec;7(4):215-22 [8130684.001]
  • [Cites] Leuk Lymphoma. 2001 Jan;40(3-4):405-11 [11426563.001]
  • (PMID = 15991005.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Viral Matrix Proteins; 0 / Viral Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


43. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs; 2003;63(8):803-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
  • Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL).
  • While the optimal use of the drug in many clinical settings has yet to be clarified, two pivotal trials have established rituximab as a viable treatment option in patients with relapsed or refractory indolent NHL, and as a standard first-line treatment option when combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (the most common type of aggressive NHL).
  • The latter was a randomised comparison of eight cycles of CHOP plus rituximab 375 mg/m(2) intravenously (one dose per cycle) versus CHOP alone in previously untreated elderly patients (60 to 80 years of age) with diffuse large B-cell lymphoma.
  • Treatment with rituximab is generally well tolerated, particularly in terms of adverse haematological effects and serious or opportunistic infections relative to standard chemotherapy.
  • CONCLUSIONS: Clinical trials with rituximab indicate that the drug has broad application to B-cell malignancies, although further clarification is needed to determine its optimal use in many of these clinical settings.
  • Importantly, rituximab in combination with CHOP chemotherapy has emerged as a new treatment standard for previously untreated diffuse large B-cell lymphoma, at least in elderly patients.
  • Compared with conventional chemotherapy, rituximab is associated with markedly reduced haematological events such as severe neutropenia, as well as associated infections.
  • Rituximab may be particularly suitable for elderly patients or those with poor performance status, and its tolerability profile facilitates its use in combination with cytotoxic drugs.
  • Although treatment with rituximab induces lymphopenia in most patients, typically lasting about 6 months, a full recovery of B lymphocytes in the peripheral blood is usually seen 9-12 months after therapy, as CD20 is not expressed on haematopoietic stem cells.
  • CD20 is, however, expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL) and to a lesser degree on B-cell chronic lymphocytic leukaemia (CLL) cells.
  • In addition, in vitro data indicate that rituximab sensitises tumour cells to the effects of conventional chemotherapeutic drugs.
  • The pharmacokinetic properties of rituximab are also characterised by wide inter-individual variability, and serum drug concentrations that are correlated with clinical response.
  • Although pharmacokinetic data are limited in patients with aggressive forms of NHL, such as diffuse large B-cell lymphoma, rituximab appears to have a similar pharmacokinetic profile in these patients to that in patients with indolent B-cell NHL.
  • The pharmacokinetics of rituximab are also reported to be similar whether the drug is administered with or without cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
  • THERAPEUTIC USE: A number of studies have demonstrated efficacy of intravenous rituximab in patients with various lymphoid malignancies of B-cell origin, including indolent (e.g. follicular lymphoma) and aggressive (e.g. diffuse large B-cell lymphoma) forms of NHL, and CLL, but the drug has not yet been approved for use in CLL, and approved indications in NHL vary between countries.
  • In the US, for example, rituximab is available for the treatment of patients with low-grade or follicular, relapsed or refractory, CD20-positive B-cell NHL.
  • In Europe, the drug has similar approval for relapsed or refractory follicular NHL as in the US, but has also been approved for use in combination with CHOP chemotherapy for the most common aggressive form of NHL (CD20-positive, diffuse large B-cell lymphoma).
  • In Japan, rituximab has been approved for indolent B-cell NHL and mantle cell lymphoma (an aggressive form of B-cell NHL), primarily on the basis of results of a Japanese phase II trial.
  • Indolent NHL: Results of several studies evaluating rituximab 375 mg/m(2) once weekly for 4 weeks in patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic lymphomas) showed objective response (OR) rates ranging from approximately 40-60% in those receiving the drug for relapsed or refractory indolent B-cell NHL, and slightly higher (50-70%) for those receiving rituximab as first-line therapy.
  • In a pivotal trial in 166 patients with relapsed or refractory low-grade or follicular B-cell NHL, intent-to-treat (ITT) analysis showed an OR rate of 48%, and a projected median time to progression of 13 months.
  • CHOP, fludarabine-containing regimens) or other drugs (e.g. interferon-alpha2a) in previously untreated patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic subtypes).
  • Follow-up data from a study in 40 patients with low-grade or follicular B-cell NHL treated with rituximab plus CHOP as first-line therapy showed that responses were durable with a progression-free survival and median duration of response >5 years.Bcl-2 gene rearrangement (t14;18) occurs in malignant cells in up to 85% of patients with follicular lymphoma, and minimal residual disease in peripheral blood and bone marrow can be monitored using polymerase chain reaction (PCR).
  • Aggressive NHL: Studies with rituximab as monotherapy in aggressive B-cell NHL, a potentially curable disorder, have generally been restricted to patients with relapsed or recurrent disease, since CHOP has traditionally been the standard first-line treatment regimen.
  • However, promising results from phase II monotherapy studies prompted further clinical investigation of rituximab in conjunction with chemotherapy.
  • Thus, most studies with rituximab in patients with aggressive forms of B-cell NHL have involved combination therapy, including a pivotal randomised trial comparing eight cycles of standard CHOP therapy plus rituximab 375 mg/m(2) (one dose per cycle) versus CHOP alone in 399 previously untreated elderly patients (60-80 years of age) with diffuse large B-cell lymphoma.
  • Other, smaller trials with rituximab in combination with CHOP or other chemotherapeutic regimens, either as first-line therapy or for patients with relapsed or refractory aggressive B-cell NHL, have also shown promising results in terms of clinical response rates.CLL: In relatively small trials (n < 40) conducted primarily in patients with relapsed or refractory B-cell CLL, rituximab monotherapy (various regimens) achieved OR rates of 23-45%, with median duration of response ranging from approximately 3-10 months. (ABSTRACT TRUNCATED)
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Drug Administration Schedule. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96 [10561023.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):21-6 [12270058.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):477-81 [12688318.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):2-9 [28140087.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Ann Hematol. 2000 Jun;79(6):332-5 [10901614.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):2961-6 [11062708.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):30-35 [28140089.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):655-61 [10442187.001]
  • [Cites] Cell Immunol. 2000 Aug 25;204(1):55-63 [11006018.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):53-61 [11226001.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1038-43 [11807010.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):81-8 [10848785.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3115-20 [12384407.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2644-52 [10914705.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):995-1001 [9818074.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):836-45 [11895917.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):105-112 [28140083.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1658-64 [12886256.001]
  • [Cites] Jpn J Cancer Res. 1998 Jul;89(7):748-56 [9738982.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1096-7 [11822361.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):928-43 [12123339.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1392-8 [11222385.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1288-94 [11870171.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1991-2 [11565541.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):399-408 [10847457.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):374-5 [10811510.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1229-30 [12414357.001]
  • [Cites] Eur J Health Econ. 2002;3(3):166-72 [15609141.001]
  • [Cites] Eur J Haematol. 2002 Sep;69(3):129-34 [12406005.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):371-6 [12416894.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):70-74 [28140094.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22 [12040530.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):259-63 [1380203.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Clin Lymphoma. 2000 Sep;1(2):146-51; discussion 152-3 [11707827.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):47-54 [10444162.001]
  • [Cites] J Immunol Methods. 1997 Mar 28;202(2):163-71 [9107305.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1735-44 [12200688.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Blood Cells Mol Dis. 2000 Apr;26(2):133-43 [10753604.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Haematologica. 2002 Jul;87(7):719-29; discussion 729 [12091123.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2672; author reply 2673 [12360978.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):697-714; discussion 714, 717, 721 [9597680.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):56-69 [28140093.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Drugs. 1999 Jul;58(1):79-88; discussion 89-90 [10439931.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29 Suppl 1:S14-7 [11840156.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):109-14 [11249036.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):280-2 [11807154.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2771-7 [11675350.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7170-6 [11156427.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):41-47 [28140091.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3800-7 [8204898.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):75-80 [28140095.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):828-34 [12060117.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Clin Lymphoma. 2000 Dec;1(3):186-94; discussion 195-6 [11707828.001]
  • [Cites] Haematologica. 1998 Mar;83(3):209-16 [9573674.001]
  • [Cites] Ann Hematol. 2000 Sep;79(9):493-500 [11043420.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:123-6 [10707793.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]
  • [Cites] Leuk Res. 2000 May;24(5):411-5 [10785263.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3449-57 [8507880.001]
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):521-6 [10482937.001]
  • [Cites] J Clin Invest. 1981 Jan;67(1):134-40 [6969730.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] Blood. 2002 Feb 1;99(3):856-62 [11806987.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):36-40 [28140090.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 12662126.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 177
  •  go-up   go-down






Advertisement